Document Type
Article
Publication Date
2017
Digital Object Identifier (DOI)
https://doi.org/10.1155/2017/9561405
Abstract
Peripartum cardiomyopathy is an uncommon, pregnancy-related form of dilated cardiomyopathy that is associated with development of new-onset left ventricular dysfunction. Its etiology is presently unknown, but current standard of care involves the use of typical drug therapy for the treatment of heart failure. Pregnancy-associated cardiomyopathy (PACM) is a similar condition that refers to patients who develop such symptoms prior to the last month of pregnancy. We report the case of a nulliparous Caucasian female who develops early, severe PACM during her first pregnancy with postpartum persistence of New York Heart Association class II-III symptoms despite medical therapy. The use of the novel heart failure agent, sacubitril/valsartan (Entresto), is initiated with near-complete resolution of her symptoms.
Rights Information
This work is licensed under a Creative Commons Attribution 4.0 License.
Was this content written or created while at USF?
Yes
Citation / Publisher Attribution
Case Reports in Cardiology, v. 2017, art. 9561405
Scholar Commons Citation
Gaddipati, Vamsi C.; Patel, Aarti A.; and Cohen, Adam J., "The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy" (2017). Internal Medicine Faculty Publications. 86.
https://digitalcommons.usf.edu/intmed_facpub/86
